MicuRx Pharmaceutical

FDA
#Antibiotic resistance #Antibiotics #FDA #MicuRx Pharmaceutical #Orphan drugs

Novel benzoxazole antibiotic gets FDA Orphan Drug Designation

MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections.  MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria (NTM).   In recent… Read More

#News #Regulatory